Statins use and the risk of all and subtype hematological malignancies: A meta-analysis of observational studies

Cancer Medicine

Volumn 4, Issue 5, 2015, Pages 770-780

  Pradelli, Danitza ^a   Soranna, Davide ^a   Zambon, Antonella ^a   Catapano, Alberico ^b,c   Mancia, Giuseppe ^a   La Vecchia, Carlo ^b,d   Corrao, Giovanni ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Hematologic malignancies; Leukemia; Myeloma; Non Hodgkin lymphoma; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CANCER RISK; DRUG USE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LEUKEMIA; META ANALYSIS; MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK REDUCTION; HEMATOLOGIC DISEASE; ODDS RATIO; PUBLICATION BIAS; RISK;

HEMATOLOGIC NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ODDS RATIO; PUBLICATION BIAS; RISK;

EID: 85006215771     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.411     Document Type: Article

References (46)

1. Sacks, F.M., M. A. Pfeffer, L. A. Moye, J. L. Rouleau, J. D. Rutherford, T. G. Cole et al. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335:1001-1009.
2. Nissen, S. E., S. J. Nicholls, I. Sipahi, P., Libby, J. S. Raichlen, C. M. Ballantyne et al. 2006. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295:1556-1565.
3. Heart Protection Study Collaborative G. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360:7-22.
4. Scandinavian Simvastatin Survival Study G. 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389.
5. Lamb, E. Top 200 drugs of 2008. Available at http://www.pharmacytimes.com/issue/pharmacy/2009/2009-05/RxFocusTop200Drugs-0509 (accessed 30 November 2009).
6. Matar, P., V. R. Rozados, M. M. Binda, E. A. Roggero, R. D. Bonfil, and O. G. Scharovsky . 1999. Inhibitory effect of lovastatin on spontaneous metastases derived from a rat lymphoma. Clin. Exp. Metastasis 17:19-25.
7. Xia, Z., M. M. Tan, W. W. Wong, J. Dimitroulakos, M. D. Minden, and L. Z. Penn . 2001. Blocking protein geranylgeranylation is essential for lovastatin induced apoptosis of human acute myeloid leukemia cells. Leukemia 15:1398-1407.
8. Gronich, N., L. Drucker, H. Shapiro, J. Radnay, S. Yarkoni, and M. Lishner . 2004. Simvastatin induces death of multiple myeloma cell lines. J. Invest. Med. 52:335-344.
9. Cocco, P., P. F. Todde, S. Fornera, P. Manca, and A. R. Sias . 1998. Mortality in a cohort expressing the glucose-6-phosphate dehydrogenase deficiency. Blood 91:706-709.
10. Jacobs, E. J., C. C. Newton, and M. J. Thun . 2011. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 71:1763-1771.
11. Chao, C., L. Xu, D. I. Abrams, W. J. Towner, M. A. Horberg, W. A. Leyden, et al. 2011. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS 25:1771-1777.
12. Lutski, M., V. Shalev, A. Porath, and G. Chodick . 2012. Continuation with statin therapy and the risk of primary cancer: a population-based study. Prev. Chronic Dis. 9:E137.
13. Landgren, O., Y. Zhang, S. H. Zahm, P. Inskip, T. Zheng, and D. Baris . 2006. Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol. Biomarkers Prev. 15:2342-2347.
14. Vinogradova, Y., C. Coupland, and J. Hippisley-Cox . 2011. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 11:409.
15. Bonovas, S., K. Filioussi, A. Tsantes, and N. M. Sitaras . 2007. Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. Br. J. Clin. Pharmacol. 64:255-262.
16. Yi, X., W. Jia, Y. Jin, and S. Zhen . 2014. Statin use is associated with reduced risk of haematological malignancies: evidence from a meta-analysis. PLoS One 9:e87019.
17. Kuoppala, J., A. Lamminpaa, and E. Pukkala . 2008. Statins and cancer: a systematic review and meta-analysis. Eur. J. Cancer 44:2122-2132.
18. Herbert, P. R., J. M. Gaziano, K. S. Chan, and C. H. Hennekens . 1997. Cholesterlol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 278:313-321.
19. Bjerre, L. M., and J. Lelorier . 2001. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am. J. Med. 110:716-723.
20. Pfeffer, M. A., A. Keech, F. M. Sacks, S. M, Cobbe, A. Tonkin, R. P. Byington et al. 2002. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 105:2341-2346.
21. Bonovas, S., K. Filioussi, N. Tsavaris, and N. M. Sitaras . 2006. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J. Clin. Oncol. 24:4808-4817.
22. Dale, K. M., C. I. Coleman, N. N. Henyan, J. Kluger, and C. M. White . 2006. Statins and cancer risk: a meta-analysis. JAMA 295:74-80.
23. Browing, D. R., and R. M. Martin . 2007. Statins and risk of cancer: a systematic review and meta-analysis. Int. J. Cancer 120:833-843.
24. Davies, H. T. O., I. K. Crombie, and M. Tavakoli . 1998. When can odds ratios mislead. BMJ 316:989-991.
25. Higgins, J. P., S. G. Thompson, J. J. Deeks, and D. G. Altman . 2003. Measuring inconsistency in meta-analyses. BMJ 327:557-560.
26. Dersimonian, R., and N. Laird . 1986. Meta-analysis in clinical trials. Control. Clin. Trials 7:177-188.
27. Deeks, J. J, D. G. Altman, and M. J. Bradburn . 2001. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. in M. Egger, G. Davey Smith, and D. G. Altman, eds. Systematic reviews in health care: meta-analysis in context. 2nd ed. BMJ Publication Group, London. http://onlinelibrary.wiley.com/doi/10.1002/9780470693926.ch15/summary
28. Egger, M., D. G. Smith, M. Schneider, M. Schneider, and C. Minder . 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634.
29. PRISMA. Transparent reporting of systematic reviews and meta analyses. Available at http://www.prisma-statement.org/statement.htm (accessed November 20, 2014).
30. Friis, S., A. H. Poulsen, S. P. Johnsen, et al. 2005. Cancer risk among statin users: a population-based cohort study. Int. J. Cancer 114:643-647.
31. Friedman, G. D., E. D. Flick, N. Udaltsova, J. Chan, C. P. Quesenberry, Jr., and L. A. Habel . 2008. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361, 859 recipients. Pharmacoepidemiol. Drug Saf. 17:27-36.
32. Traversa, G., F. Menniti-Ippolito, R. Da Cas, A. Mele, A. Pulsoni, and F. Mandelli . 1998. Drug use and acute leukemia. Pharmacoepidemiol. Drug Saf. 7:113-123.
33. Blais, L., A. Desgagné, and J. LeLorier . 2000. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch. Intern. Med. 160:2363-2368.
34. Graaf, M. R., A. B. Beiderbeck, A. C. Egberts, D. J. Richel, and H. J. Guchelaar . 2004. The risk of cancer in users of statins. J. Clin. Oncol. 22:2388-2394.
35. Zhang, Y., T. R. Holford, B. Leaderer, S. H., Zahm, P. Boyle, L. M. Morton et al. 2004. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15:419-428.
36. Fortuny, J., S. de Sanjosé, N. Becker, M., Maynadié, P. L. Cocco, A. Staines et al. 2006. Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH. Cancer Epidemiol. Biomarkers Prev. 15:921-925.
37. Iwata, H., K. Matsuo, S. Hara, K., Takeuchi, T. Aoyama, N. Murashige et al. 2006. Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci. 97:133-138.
38. Coogan, P. F., L. Rosenberg, and B. L. Strom . 2007. Statin use and the risk of 10 cancers. Epidemiology 18:213-219.
39. Emberson, J.R., P. M. Kearney, L. Blackwell, C., Newman, C. Reith, N. Bhala et al. 2012. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175, 000 people in 27 randomised trials of statin therapy. PLoS One 7:e29849.
40. Goldstein, M. R., L. Mascitelli, and F. Pezzetta . 2008. Do statins prevent or promote cancer? Curr. Oncol. 15:76-77.
41. Sassano, A., E. Katsoulidis, G. Antico, J. K., Altman, A. J. Redig, S. Minucci et al. 2007. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res. 67:4524-4532.
42. Chapman-Shimshoni, D., M. Yuklea, J. Radnay, H. Shapiro, and M. Lishner . 2003. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp. Hematol. 31:779-783.
43. Hindler, K., C. Cleeland, E. Rivera, and C. Collard . 2006. The role of statins in cancer therapy. Oncologist 11:306-315.
44. Habel, L. A., and G. D. Friedman . 2006. Pharmaceuticals other than hormones. Pp. 489-506 in D. Schottenfeld, J. F. Fraumeni, Jr., eds. Cancer epidemiology and prevention. 3rd edn. Oxford University Press, New York, N. Y.
45. Kuliszkiewicz-Janus, M., R. Małecki, and A. Mohamed . 2008. Lipid changes occurring in the course of hematological cancers. Cell. Mol. Biol. Lett. 13:465-474.
46. Bellosta, S., R. Paoletti, and A. Corsini . 2004. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109(Suppl. 1):III50-III57.